Project Grant R01AG085296

Award Date 8/15/24
Completion Date 4/30/29
Dollars Obligated $3.6M
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Fort Worth, TX 76107, USA
Similar Awards
The National Institutes of Health National Institute on Aging awarded $3,024,000 under the Aging Research federal grant program (CFDA 93.866) to the Massachusetts General Hospital on September 30, 2022 for a project concluding on August 31, 2025. The award will support research into discovering sex-linked genes on the inactive X chromosome that may influence female vulnerability to Alzheimer's disease pathology. The awardee will employ genomic, transcriptomic, and epigenetic analysis to...
This Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the interaction between biological sex and APOE genotype in modulating Alzheimer's disease (AD) risk. The research will leverage human induced pluripotent stem cell lines with various APOE genotypes and sex chromosome complements to examine how APOE and sex influence amyloid-beta processing, tau hyperphosphorylation, and transcriptional changes...
The Washington University in St. Louis, Office of Sponsored Research Services Division, received a $2,133,060 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866). The grant will support research to investigate the sex-dependent effects of stress on the accumulation of amyloid-beta (Aβ) and tau proteins, which are hallmarks of Alzheimer's disease pathology. The study aims to elucidate the signaling pathways that mediate the differential...
The National Institute on Aging (NIA) awarded Arizona State University (ASU) a $851,002 Project Grant (CFDA 93.866 - Aging Research) on December 15, 2024 to conduct a "Systematic Investigation of Genetic Contributions of Sex Chromosomes to Alzheimer's Disease". The project will re-align and analyze large amounts of next-generation sequencing data from Alzheimer's disease cohorts to investigate the genetic contributions of sex chromosomes to the sex differences observed in Alzheimer's...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $815,215 to Yale University to conduct a multimodal imaging study examining sex-based contributors to vulnerability to Alzheimer's disease (AD). The study aims to leverage a new prospective cohort and open-source datasets to understand the impact of sex and sex-based factors, such as reproductive period and APOE genotype, on functional brain networks and the progression of tau pathology in...
The National Institute on Aging (NIA) awarded a $1,558,726 Project Grant under the Aging Research program (CFDA 93.866) to the University of Pittsburgh. The grant, titled "MENOBRAIN: A Longitudinal Investigation of Menopause and Brain Health," will conduct a 5-year study to elucidate the brain and cognitive changes that occur during the perimenopause phase of the menopause transition, and the factors contributing to these changes. The study will recruit 224 women in the late...
This $3.5 million project grant from the National Institutes of Health's National Institute on Aging will fund research into sex differences related to epigenetic parent-of-origin effects and Alzheimer's disease. The Regents of the University of California, San Francisco will investigate how the maternal versus paternal X chromosome impacts neural vulnerability to Alzheimer's-related deficits in mouse models and primary neurons. The researchers hypothesize that imprinting or silencing of genes...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $185,913 to Trustees of Boston University to examine sex differences in vascular contributions to cognitive impairment and dementia (VCID) and Alzheimer's disease (AD). The research aims to identify sex-specific patterns of white matter integrity, functional brain connectivity, and cognitive...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $429,000.00 to the University of Texas Health Science Center at Houston (UTHealth) to study the impact of Alzheimer's disease pathogenesis on the activity of corticotropin releasing factor (CRF) neurons and regulation of the hypothalamic-pituitary-adrenal (HPA) axis. The research aims to identify a direct mechanism connecting Alzheimer's disease progression with dysregulation of the...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), is focused on investigating the association between the Alzheimer's disease (AD) risk gene APOE4 and the menopause-related hormone follicle-stimulating hormone (FSH) in the initiation and progression of AD, particularly in women. The $564,530 award to Emory University will support research to explore how APOE4 may facilitate AD pathology in women by interacting with FSH-induced...

This Project Grant award of $3,558,527.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to investigate the interaction between sex chromosomes, sex hormones, brain-derived hormones, and brain angiotensin II activation on accelerated brain aging and cognitive decline in Alzheimer's disease. The award was granted to the University of North Texas Health Science Center at Fort Worth and will fund a 5-year study with specific objectives to: 1) Determine the role of circulating hormones on modulating brain angiotensin II-associated oxidative stress and cognitive impairment, 2) Examine the role of brain-derived hormones on modulation of angiotensin II-associated oxidative stress and cognitive impairment, and 3) Determine the independent effects of sex hormones and sex chromosomes on angiotensin II-associated oxidative stress and cognitive impairment. The goal is to elucidate mechanisms underlying the observed sex differences in Alzheimer's disease risk, in which post-menopausal women are at the highest risk.

Generated 8/5/25, 5:21 AM